This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
PureHale® & The Future of Fine Mist Dispensers for Upper Airway Treatments
Publications, Pharmaceutical, Drug Delivery Innovations, Brand Differentiation, Market Insights, Product Solutions
Acute Migraine Relief: Nose-to-Brain Delivery with Lipid Nanoparticles
Publications, Pharmaceutical, Market Insights, Product Solutions, Drug Delivery Innovations
Understanding PBPK Modeling in OINDPs: Insights from Will Ganley
Publications, Pharmaceutical, Market Insights, Product Solutions
Advancing Nose to Brain Drug Delivery: Intranasal Administration of Insulin
Publications, Pharmaceutical, Innovation & Insights, Drug Delivery Innovations, Market Insights, Product Solutions
